QTZ（Cat No.:I043490）is a selective small molecule inhibitor that targets the protein kinase CK2 (casein kinase 2), an enzyme involved in regulating various cellular processes, including cell cycle progression, apoptosis, and signal transduction. CK2 is often overactive in cancer cells, contributing to uncontrolled cell growth and resistance to treatment. By inhibiting CK2, QTZ aims to block these oncogenic processes, reducing tumor proliferation and enhancing the effectiveness of other therapies. This compound is being studied for its potential in treating cancers and other diseases where CK2 dysregulation plays a critical role in disease progression.